期刊文献+

胃癌患者内皮细胞微颗粒的检测及其意义

Detection of Circulating Endothelial Micropaticles in Patients with Gastric Cancer and Its Clinical Significance
原文传递
导出
摘要 目的比较胃癌患者与正常对照组血浆中内皮细胞微颗粒(EMPs)、血管性血友病因子(vWF)水平的变化,探讨EMPs检测在胃癌中的意义。方法采用流式细胞术及酶联免疫吸附试验(ELISA)检测68例胃癌患者和20例正常对照者血浆中EMPs、vWF的水平,分析这些指标与临床特征的关系。结果胃癌患者血浆vWF及EMPs水平显著高于正常对照组(P<0.01),血浆vWF及EMPs水平Ⅲ、Ⅳ期患者高于Ⅰ、Ⅱ患者(P<0.01),有淋巴结及肝转移者高于无淋巴结及肝转移者(P<0.01),有静脉浸润者高于无静脉浸润者(P<0.01),浸润至肌层、浆膜层者高于浸润至黏膜或黏膜下层者(P<0.01)。结论血浆EMPs可准确反映内皮功能,内皮功能紊乱参与胃癌的转移过程,EMPs可作为判断胃癌的病情、预后、疗效的指标之一。 Objective To Compare the levels of endothelial microparticles( EMPs) and vWF in paients with gastric cancer and in the controls,to explore the significance of the EMPs in gastric cancer. Methods Both in 68 cases of gastric cancer and 20 cases of healthy controls,circulating EMPs were numerated by flow cytometry and plasma vWF was measured by the enzyme linked immunosorbent assay to explore the relationships between the level of EMPs and the clinical feathures. Results The levels of EMPs and vWF in patients with gastric cancer were significantly higher than those in the controls( P 0. 01) . EMPs and vWF concentrations were remarkablely higher in patients with stage Ⅲ,Ⅳ; lymph node or liver metastasis and venous invasion. Conclusion The levels of EMPs can exactly reflect the endothelial function and measurement of plasma EMPs might be useful for diagnosis as a biomarker and prognosis. EMPs may play an important role in the metastasis of gastric cancer.
出处 《苏州大学学报(医学版)》 CAS 北大核心 2010年第5期1055-1057,共3页 Suzhou University Journal of Medical Science
关键词 内皮细胞 微颗粒 胃癌 诊断 endothelial microparticles gastric caner diagnosis
  • 相关文献

参考文献1

二级参考文献11

  • 1[1]Karen BG, Roy LS. Hypercoagulability in cancer. Hematoi Oncol Clin North Am, 1996; 10(2) :499.
  • 2[2]Manuel M, Paolo P. Venous thromboembolism as first manifestation of cancer. Seminars in Thrombosis and Hemastasis, 1999, 25 (2):131.
  • 3[3]Monreal M, Lafoz E, Casals, et al. Occult cancer in patients with deep venous thrombosis: a systematic approach. Cancer, 1991,67: 541.
  • 4[4]Piccioli A, Prandoni P, Ewenstein BM, et al. Cancer and venous thromboembolism. Am Heart J, 1996. 132:850.
  • 5[5]Anna, F, Frederick RR, Pathophysiology of the thrombophilic state in the cancer patient. Seminars in Thrombosis and Hemostasis 1999,25(2): 173.
  • 6[6]John LF, John B, Ali A. Hemostasis and malignancy. Seminars in Thrombosis and Hemostasis, 1998,24 (2): 93.
  • 7[7]Paolo P, Andrea P, Antonio G, Cancer and venous thromboembolism: An overview. Haematologica, 1999,84: 437.
  • 8[8]Falanga A, Consonni R, Marchetti M, et al. Cancer procoagulant and tissue factor are differently modulated by all-trans-retinoic acid ( ATRA) in acute promyelocytic leukemia cells. Blood, 1998,92: 143.
  • 9[9]Shoji M, Hancock WW, Abe K, et al. Activation of coagulattion and angiogenesis in cancer. Immunohistochemical localization in situ of clotting proteins and VEGF in human cancers. Am J Pathol, 1998,152:399.
  • 10[10]Agnes YYL, Mark NL. The thrombophilic state induced by therapeutic agents in the cancer patient. Seminars in Thrombosis and Hemostasis, 1999,25 (2): 137.

共引文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部